Stein MN, Vinceneux A, Robbrecht D, Doger B, et al. Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study. J Clin Oncol 2025 Jun 1:101200JCO2500678. doi: 10.1200/JCO-25-00678.
PMID: 40450573